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In this study we used the fungal antibiotic brefeldin A (BFA) to analyze its effect on viral replication.
Analysis by electron microscopy demonstrated that no viral particles were observed in cells treated
before the onset of viral replication. In the presence of BFA expression of IE2, MCP, pUL104, pUL56
and pUL89 were reduced, while no or slight effect was observed on expression of pp65, pUL44 and
pUL57. Strikingly, real time PCR revealed that de novo viral DNA synthesis is reduced but not com-
pletely abolished in the presence of BFA. These results indicated that BFA represents a multi-func-
tional compound leading to inhibition of several steps of viral maturation such as expression of
viral DNA packaging proteins and capsid formation.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Genome packaging of human cytomegalovirus (HCMV) is the
fundamental step in viral maturation. The double-stranded DNA
has to be encapsidated into an assembled icosahedral procapsid.
This process requires condensation of the large dsDNA to nearly
crystalline structure and therefore needs a so-called nanomotor
to provide the necessary energy [1,2]. One component of the nano-
motor are terminases. Terminases were ﬁrst described as speciﬁc
enzymatic proteins for double-stranded DNA bacteriophages with
multiple activities required for the whole packaging process
[3,4]. Terminases are heteromultimers whereas each subunit has
a different function. While the small subunit is required for binding
to the DNA, the large subunit that has besides an endonuclease
activity an ATPase activity mediating the translocation of DNA into
the preformed capsid [5–9].
More recently, we have demonstrated that the HCMV packaging
machine consists of the large and small terminase subunits, pUL56
and pUL89, and the portal protein pUL104, respectively [10–14].
pUL56 recognizes the concatemeric viral DNA and threads it into
the packaging machine [15]. Due to its open ring-shaped structure
pUL56 could bind and release DNA [16]. ATP hydrolysis by pUL56
provides the energy for packaging [17]. It is a common opinion thatchemical Societies. Published by E
).the driving force for DNA packaging is conversion of chemical to
mechanical energy, thus leading to repetitive conformational
changes of the packaging enzymes. Various models of the motor
force of viral DNA packaging motors have been discussed (for re-
view [18]). The latest model proposes different conformations of
the terminase protein gp17 of bacteriophage T4. The authors sup-
posed that alternating changes between tensed and relaxed states
represent the electrostatic force for DNA packaging [19]. pUL89 is
responsible for site-speciﬁc duplex nicking of the concatemers
[11]. After DNA packaging the capsids undergo two sequential bud-
ding events, one during nuclear egress and the other during ﬁnal
envelopment at the trans-Golgi network (TGN).
HCMV maturation has been studied by using the drug brefeldin
A (BFA; [20]). BFA is a fungal metabolite effecting cellular organ-
elles, leading to disruption of the vesicular system [21,22]. BFA
was initially characterized as an antiviral antibiotic [23] showing
antiviral activity against enveloped viruses. It prevents the vesicu-
lar transport of glycoproteins from the ER to the TGN. Therefore the
ﬁnal envelopment at the TGN or for some viruses at the plasma
membrane is inhibited [20,24,25]. In non-enveloped viruses
including poliovirus the compound inhibits viral genome replica-
tion [26,27]. In a previous study it was shown that short-term
treatment prevents envelopment of cytoplasmic capsids and there-
fore viral maturation while budding at the nuclear membranes
were not effected [21]. In addition, long-term treatment (from
12 h p.i.) leads to inhibition of DNA synthesis. In this studylsevier B.V. All rights reserved.
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that is blocked in the presence of BFA.2. Materials and methods
2.1. Cells and viruses
Human foreskin ﬁbroblasts (HFF) were grown in Dulbecco’s
minimal essential medium (DMEM) supplemented with 10% fetal
calf serum (FCS), 2 mM glutamine and gentamycin (60 lg/ml).
HFF cells at passages 10–15 were used for infections. Experiments
were carried out with conﬂuent cell monolayers. Preparation of
HCMV AD169 was performed after infection of HFF cells at MOI 0.1.
2.2. Inhibitor
Brefeldin A (BFA; CAS 20350-15-6; Sigma) was dissolved in
methanol (MeOH) at a concentration of 3.5 mM. Stock solution
was stored at 20 C. Experiments were performed with concen-
trations of 3.5 lM and 0.035 lM. Since no difference was observed
and a complete block of viral replication was achieved at a concen-
tration of 0.035 lM the latter was used in this study. BFA was
added at various time points post infection as indicated.
2.3. Cytotoxicity determination
Cytotoxicity (CC50) proﬁling of BFA was determined by using
Cell Proliferation Kit II (XTT, Roche) as recommended by the
manufacturer.
2.4. Immunoﬂuorescence
For immunoﬂuorescence, HFF cells were grown on cover slips.
At the appropriate time point, cells were ﬁxed with 3% paraformal-
dehyde as described previously [28]. For double staining HCMV
pUL56-speciﬁc pAbUL56 and pUL112–113-speciﬁc antibody mAb
M23 were used in the ﬁrst incubation. In the second incubation
Cy2-labeled anti-human and Cy3-labeled anti-mouse F(ab0)2
fragments were used as secondary antibodies. Nuclei were stained
using TOPRO3. After staining the samples were mounted in Fluoro-
prep (bioMerieux, France) containing 2.5% (w/v) 1,4-Diazabicy-
clo[2.2.2]octan and examined by immunoﬂuorescence
microscopy using a Carl Zeiss Laser Scanning Microscope LSM
510/ConfoCor2. Images were processed using the Axioplan soft-
ware program (Carl Zeiss) and embedded into PowerPoint,
respectively.
2.5. BrdU labeling and immunostaining
HFF (5  105) were grown on cover slips, infected at MOI 1 and
treated at 6, 24 or 48 h p.i. with 0.035 lM BFA or left untreated.
BrdU (10 lM) was added at 45 h p.i. Cells were ﬁxed at 72 h p.i.
and DNA was denatured in 2 N HCl for 30 min at 37 C followed
by neutralization with 1 TBE. Immunostaining was carried out
using mAb a-BrdU (Dianova) for 45 min at RT prior to incubation
with Cy3 labeled goat anti-mouse F(ab0)2 fragments. Nuclei were
stained using DAPI. Samples were mounted as described above.
Images were captured with a Carl Zeiss Laser Scanning Microscope
LSM 710/ConfoCor3 in conjunction with VisArt (Carl Zeiss; A. Hor-
ch kindly made the LSM710 available to our research).
2.6. Plaque reduction assay
HFF cells (1  105) were seeded in 24-well plates and infected
at MOI 0.01. After adsorption the inoculum was replaced with2 ml methyl cellulose (Methocel MC, Fluka) containing DMEM,
3% FCS and 0.035 lM BFA. At day 7 p.i. cells were stained with
mAb E13 against IE1/2 for 1 h at 37 C prior to incubation with
HRP conjugated anti-mouse F(ab0)2 fragments for 2 h. By using
the AEC-Staining Kit (Sigma) plaques were dyed red and enumer-
ated by microscopic counting. Plaques were counted for determi-
nation of the 50% inhibitory concentration (IC50) of BFA by
comparing drug-treated to untreated cells.
2.7. Growth characteristics
HFF cells (1  105 cells per well) were seeded in 24-well culture
plates. Conﬂuent cells were infected with AD169 at MOI 1 in the
absence or presence of 0.035 lM BFA. At 24, 48, 72 and 96 h p.i.
the supernatants were harvested for determination of titers using
plaque reduction assay as described above.
2.8. SDS–PAGE and Western blot
HFF cells (3  106) were infected with AD169 at MOI 1 in the
presence or absence of 0.035 lM BFA. Cells were harvested at
72 h p.i., freeze–thawed and centrifuged at 2000g for 30 min at
4 C. Supernatants were separated on 10% (w/v) polyacrylamide
gels, transferred to nitrocellulose sheets and subjected to Western
blot analysis. The antibody pAbUL56 (1:10) speciﬁc for pUL56, pA-
bUL89 speciﬁc for pUL89, pAbUL104 speciﬁc for pUL104 and
monoclonal antibodies CH167, BS510, 58-15 and 28-4 speciﬁc for
pUL57, pUL44, pp65 and MCP, respectively, were used as the pri-
mary antibody prior to incubation with horseradish peroxidase-
conjugated anti-human (1:10000), anti-rabbit (1:3000) or anti-
mouse (1:3000)F(ab0)2 fragments. The membranes were probed
with an antibody against b-actin (1:5000) and horseradish peroxi-
dase-conjugated anti-mouse (1:5000) F(ab0)2 fragments. Detection
of protein bands was performed using ECL reagent (Pierce).
2.9. Thin sectioning and electron microscopy
HFF cells (T-25 cm2 ﬂasks, 1  106 cells) were infected with
HCMV AD169 at MOI 1. At 6, 24, or 48 h post infection 0.035 lM
BFA was added or cells were left untreated. Cells were ﬁxed and
embedded as described before [29]. Sections were analyzed using
a Tecnai G2 (FEI Company, Eindhoven, Netherlands) electron
microscope operated at 120 kV. Micrographs were recorded with
a 2K MegaView III digital camera (Olympus Software Imaging Solu-
tions) at calibrated magniﬁcations.
2.10. Preparation of DNA
For quantiﬁcation of viral DNA HFF cells (T-75 cm2 ﬂasks,
3  106 cells) were infected with HCMV AD169 at MOI 1. At 0,
24, or 48 h post infection 0.035 lM BFA was added or cells were
left untreated. Three days p.i. cells were harvested and DNA was
isolated using QIAamp DNA Mini Kit (Qiagen, Germany) according
to the instruction of the supplier.
2.11. Real-time quantiﬁcation PCR
Amounts of viral DNA were determined by quantiﬁcation of
real-time PCR. Oligonucleotides for real-time PCR amplifying
US17 were synthesized by BioTeZ (Berlin, Germany): US17-fwd
50-AAAAGTTTGTGCCCCAACGGTA-30/US17-back 50-GCGTGCTTTTT
AGCCTCTGCA-30. Real-time PCR was performed using 5 ll of DNA
and 4 ll LightCycler FastStart DNA Masterplus HybProbe (Roche,
including FastStart Taq DNA polymerase, dNTPs and 3.5 mM
MgCl2), 500 nM US17 primers in a ﬁnal volume of 20 ll. After acti-
vation of the polymerase at 95 C for 10 s, 55 cycles of ampliﬁca-
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2.0 (Roche Diagnostics). Two control probes with ﬂuorescent tags
(150 nM each) were used [CM 10F: FAM-50-TGATCGGCGTTA
TCGCGTCTCTGATC-30-TAMRA (BioTeZ) and for the internal control
LM 1 Dy: DYXL-50-ACCTTACCGAAATCGGTACGGATACCGC-30-BHQ-
2 (TIB MOLBIOL, Berlin)]. Primers for the ampliﬁcation of the con-
trols were the same as for the probe (US17). In the assay we used
one negative (FCS) and one positive control (HCMV DNA, 3.2 copies
per ll) as well as two standards, std N (39 copies/ll) and std H
(3.9  102 copies/ll). The standards were prepared by serial dilu-
tions from 0.75 to 1.6  104 copies per ll.
2.12. Biostatistical analysis
In order to determine the efﬁciency of BFA on the decrease in
mRNA, plaque formation andWestern blot statistical analysis were
performed. The results obtained from paired Student’s t-test were
used to calculate signiﬁcance. A P-value of <0.05 was considered
signiﬁcant.
3. Results
3.1. Effects of BFA on replication
Impacts of BFA were quantiﬁed by measurement of: (i) viral
plaque formation, (ii) growth kinetics and (iii) effects of different
concentrations on HCMV replication (data not shown). For deter-
mination of the 50% inhibitory concentration (IC50), plaque reduc-
tion assays were performed. The mean IC50 was 0.019 lM while
the mean 50% cytotoxic concentration (CC50) was 0.146 mM. Sin-
gle-cycle growth curves were performed using cells infected in
the presence or absence of 0.035 lM BFA in order to determine ef-
fects on replication. As shown in Fig. 1 a signiﬁcant difference in
yield and kinetics of infectious virus production was observed.
3.2. Interference of BFA with viral particles formation
To investigate whether infectious particles were formed in the
presence of BFA electron microscopic analysis was performed.
HFF cells were infected with HCMV AD169 at MOI 1 and treated
with 0.035 lM BFA from 6, 24 and 48 h p.i. or left untreated. Cells
were harvested at 72 h p.i. In infected cells grown without the
compound all types of capsids were found in the nuclei (Fig. 2A).
In addition, infectious particles as well as non-infectious deﬁcient0
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Fig. 1. Growth kinetics in the presence of BFA. HFF cells were infected with HCMV
AD169 at MOI 1 in the absence or presence of 0.035 lM BFA. At each time point
supernatants were harvested and used to infect conﬂuent HFF cells in order to
determine progeny virus titers were by plaque reduction assay. Error bars are ±S.D.
from three different experiments.enveloped particles, the so-called dense bodies (db), were observed
in the cytoplasm or in the extracellular space (Fig. 2B). In contrast
cells treated with BFA from 6 h after infection did not show any
capsids or viral particles (Fig. 2C and D). In cells treated 24 h p.i.
very few B capsids were sporadically observed in the nucleus
(Fig. 2E and Table 1). Only in cells treated at late times after infec-
tion (48 h p.i.) all types of capsids and viral particles could be ob-
served in comparable amounts to untreated cells (Fig. 2G and H
and Table 1). To investigate whether these effects are due to BFA
treatment and not a result of apoptosis, cells were treated for
24 h prior to removal of BFA. Electron microscopic analyses were
performed using cells treated with 0.035 lM BFA for 24 h, com-
pound was removed and cultured for additional 48 h. After BFA re-
moval all types of capsids with an equal distribution compared to
untreated cells (Fig. 2I) as well as infectious virions and dense
bodies (Fig. 2J) were observed. These results demonstrated that
the effects of BFA are not due to apoptosis. In summary the exper-
iments demonstrated that at early times post infection BFA blocks
viral maturation completely and at 24 h post infection BFA pre-
vents viral DNA packaging and leads to abolished capsid assembly.
3.3. BFA treatment prevents formation of replication centers
In order to analyze whether BFA has an inﬂuence on formation
of replication centers intracellular localization of the terminase
subunit pUL56 and the gene products encoded by the ORFs
UL112–113, four proteins that are required for DNA replication,
were examined by confocal immunoﬂuorescence. As expected in
infected cells and after late treatment in the infectious cycle
(48 h p.i.) pUL56 as well as pUL112–113 were localized in replica-
tion centers where DNA synthesis occurs (Fig. 3D–G; P–S
[20,21,30]). In contrast incubation in the presence of BFA with
treatment starting at 6 h or 24 h p.i. led to a changed distribution
as well as a reduced expression of the investigated proteins. The
large terminase subunit and pUL112–113 were translocated to
the so-called pre-replication compartments formed by the gene
products of UL112–113 (Fig. 3H–K, L–O).
3.4. BFA does not prevent de novo synthesis of viral DNA
Due to the virus-host shutoff in HCMV infected cells the nucle-
otide analog BrdU is preferably incorporated into newly synthe-
sized viral DNA. Non-infected and HCMV infected HFF (MOI 1)
were cultured with or without BFA (0.035 lM) for 45 h before add-
ing 10 lM BrdU. Cells were cultured for additional 27 h and subse-
quently stained with mAb a-BrdU. Untreated as well as treated
cells showed a BrdU staining pattern. While treatment from 6 or
24 h p.i. led to a diffuse staining in the nucleus, in cells treated
from 48 h p.i. and untreated cells bright nuclear patches were ob-
served (Fig. 4A). Non-infectious cell (mock) or cells incubated with
the solvent (MeOH) served as controls. The latter localization is
consistent with ongoing viral DNA replication, thus indicating that
BFA had an inﬂuence on DNA synthesis resulting in an altered nu-
clear localization.
To investigate whether any DNA replication occurs in the pres-
ence of BFA real-time quantitative PCR analyses were performed.
HCMV infected HFF (MOI 1) were cultured with BFA (0.035 lM)
for 72, 48, 24 h or left untreated. After harvesting the cells at
72 h p.i. the DNA was extracted and used for quantiﬁcation of
US17 copy numbers. Interestingly DNA synthesis was observed in
all samples. However, in cells treated with BFA from the beginning
of infection (for 72 h) the difference to untreated cells was 6-fold,
while treatment for 48 or 24 h only leads to approximately 2-fold
reduction of copy numbers (Fig. 4B). These results demonstrated
that BFA does not lead to an abolished but reduction of de novo vir-
al DNA synthesis.
Fig. 2. Transmission electron micrograph of thin sections. Infected HFF cells were treated with 0.035 lM BFA from 6 h (C, D), 24 h (E, F), 48 h (G, H) or BFA was added 0 h p.i.
and removed 24 h (I, J) after infection or left untreated (A, B). Analysis by EM was performed at 72 h post infection. A, C, E, G and I represent an area in the nucleus while B, D,
F, H and J show a section of the cytoplasm. B capsids are indicated by bold black arrows, A capsids by bold gray arrows, C capsids by white arrows and virion by black arrows.
Extracellular virions are shown in the integrated small ﬁgures. The scale bars correspond to 200 nm.
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To further investigate the impact of BFA on the expression of
immediate-early (IE), early (E) and late (L) proteins Western blot
analysis was carried out. Untreated AD169 infected cells (MOI 1),
cells treated with 0.035 lM BFA at 0, 6, 24 or 48 h p.i. or treatedat 6 h p.i. for 24 h prior to removal and additional incubation for
48 h p.i. were subjected to immunoblot analysis using antibodies
against immediate-early-proteins IE1, IE2, early proteins pUL44,
pUL57, early/late proteins, pp65, pUL89, pUL56, pUL104 and the
late protein MCP. Equal amount of proteins in all samples were
conﬁrmed by using b-actin. Expression of the late protein MCP
Table 1
Nuclear capsids of infected cell in the presence of 0.035 lM BFA.
Treatment from No. of capsid forms per nucleus (%)
A B C
6 h p.i. nd nd nd
24 h p.i. nd 100a nd
48 h p.i. 19.2 50.0 30.7
w/o 20.0 58.8 21.3
Recovery 16.7 63.4 20.0
nd, not detected.
a Only 3 B-capsids per nucleus.
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ment, while expression of the early protein pUL44, the processivity
factor of the viral DNA polymerase and the early–late protein pp65
remained unchanged (Fig. 5). Long-term BFA treatment resulted in
slightly reduced expression of pUL57, the single-stranded binding
protein, and clear reduction of IE2, the terminase subunits pUL56Fig. 3. Intracellular distribution of pUL56 in BFA treated infected cells. Mock-infected (A
double stained with pAbUL56 and mAb M23 directed against pUL56 and pUL112–113, r
scanning confocal microscopy. A merge of Cy2 and Cy3 stained cells is shown in the rigand pUL89 and the portal protein pUL104 (Fig. 5). Treatment start-
ing at 48 h p.i. had no inﬂuence on protein expression (Fig. 5). In
addition, treatment prior to the onset of viral replication combined
with removal of the drug after 24 h p.i. resulted in an expression of
immediate-early, early and late proteins comparable to untreated
cells (Fig. 5, recov.).
4. Discussion
It has been shown that the fungal metabolite Brefeldin A is an
effective inhibitor of herpesviruses due to its disruption of secre-
tory pathway-dependent transport [20,24,32,33]. In extend to
our previous observations [20] we demonstrated that long-term
treatment starting as early as 6 h after infection completely
inhibited formation of procapsids as well as non-infectious par-
ticles (e.g. dense bodies or NIEPS) and virions. Only reduced
amounts of procapsids were observed. In addition, viral DNA
packaging as well as budding of capsids through the nuclear
membranes was prevented after 48 h of BFA treatment. How-, C), infected cells untreated (w/o; D–G) or treated with BFA (H–K, L–O, P–S) were
espectively. The images represent the central section of the cells analyzed by laser
ht panel. Cell nuclei were stained with TOPRO3.
BFA addition Real-time PCR
Copy numbers (x 106)
Effects of BFA on DNA synthesis (copies per µl) 
0 h 2.51   ± 0.27 0.025
24 h 7.82   ± 0.35                n.s.
48 h 10.65  ± 0.49 n.s.
w/o 10.52  ± 1.84
A
B
MeOH6h BFA 24h BFA 48h BFA w/o mock
P value (w/o)
n.s., not significant
Fig. 4. Analysis of de novo DNA synthesis in BFA treated cells. (A) HCMV infected HFF (MOI 1) were cultured with (BFA) or without (w/o) BFA from 6, 24 and 48 h post
infection. BrdU (10 lM) was added at 45 h after infection. Cells were cultured for additional 27 h prior immunoﬂuorescence staining using mAb a-BrdU. (B) DNA of HCMV
infected cells treated at 0, 24 and 48 h p.i. with 0.035 lM BFA or left untreated was prepared and subjected to realtime PCR.
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had no effect on viral maturation, as demonstrated by the bud-
ding events of C-capsids and observed cytoplasmic virions. In
contrast to our observation Whealy et al. [33] reported that
short-term treatment of PRV-infected cells resulted in the accu-
mulation of enveloped particles in the perinuclear space and in
the ER, suggesting an effect of BFA on nuclear egress. In HSV-1BFA
6h 24hw/o 0h
Fig. 5. Analysis of HCMV protein expression in BFA treated cells. HCMV infected cells
respectively, or treated at 6 h p.i. for 24 h prior to removal and additional incubation for
pUL44, pUL57, pUL104, pUL56, pUL89, pp65 and MCP. Membranes were re-probed with
proteins.infected cells it was demonstrated that the primary effect of
BFA is inhibition of nuclear egress because short-term treatment
prevents envelopment of C-capsids [24]. However, an earlier re-
port described that in HSV-1 long treatment with BFA did not
prevent the formation of C-capsids and their release into the
cytoplasm [34]. It seems that in alphaherpesivurses the effects
caused by BFA lead to other phenotypes than in betaherpesvirus-IE 2
pUL56
pUL44
Actin
MCP
IE 1
48h recov.
pp65
pUL89
pUL57
pUL104
untreated (w/o) or cells treated with 0.035 lM BFA added at 0, 6, 24 and 48 h p.i.
48 h p.i. were subjected to Western blot analysis using antibodies against IE1/IE2,
an antibody against b-actin to verify equal loading. Arrows indicate the position of
O. Kregler et al. / FEBS Letters 583 (2009) 1207–1214 1213es like HCMV. In our study we showed that in HCMV BFA affects
earlier steps in the infectious cycle than viral egress.
If BFA was added at early times after infection the terminase
subunit pUL56 and the proteins pUL112–113 were translocated
into punctuate structures, the so-called pre-replication compart-
ments, while short-term treatment (from 48 h) led to the known
localization of proteins in replication centers [31,35]. This indicates
that viral replication is inhibited after long-term treatment. Fur-
thermore, the addition of BFA at early time points after infection
(6 h p.i.), prior to the onset of structural gene expression, had no
effect on expression of pUL44, the processivity factor required for
viral DNA replication and pp65, an abundant tegument protein.
Expression of the single-stranded binding protein pUL57 is re-
duced but not inhibited during long-term treatment. This suggests
that synthesis of early–late genes is maintained even after long-
term BFA treatment. These results sufﬁciently did not shed light
on the primary mode of action of BFA. The question raises whether
viral maturation is blocked at the point of structural protein
expression or whether the block already occurs during DNA syn-
thesis. Analysis using BrdU demonstrated that BFA leads to a
homogeneous nuclear distribution of newly synthesized DNA in-
stead of a condensed localization in replication centers. Strikingly,
real time quantitative PCR demonstrated that BFA treatment did
not completely shut down de novo DNA synthesis. The reduction
after long-term treatment was only 6-fold compared to untreated
samples, but the copy number of approximately 3  106 is still very
high. Therefore DNA synthesis is not explaining the observed effect
by BFA. However, protein synthesis of IE2 and the single-stranded
binding protein pUL57 was slightly and pUL56, pUL89, pUL104 and
MCP synthesis was almost completely inhibited. It is generally ob-
served that IE2 is slightly inhibited when DNA synthesis is reduced
(Mark Stinski, University of Iowa, USA, personal communication).
Expression of genes involved in packaging was completely abol-
ished by long-term treatment, thus explaining the absence of prog-
eny virus observed using electron microscopy. It is yet unclear how
BFA affects viral protein expression. A possible explanation could
be a reduced expression of viral proteins due to numerous altera-
tions of cellular compartments during BFA treatment.
Therefore we concluded that the primary effect of BFA is the
block of expression of several essential viral proteins among
them are the proteins of the packaging motor consisting of the
terminase and the portal protein as well as the major capsid
protein (MCP) resulting in the absence of cleavage/packaging
unit-length genomes and a decrease of capsid formation. Taken
together, we demonstrated that BFA is at least a multiple func-
tional drug leading to inhibition of several steps of viral matura-
tion like capsid formation as well as expression of viral DNA
packaging proteins.Acknowledgments
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